In vitroinduction of specific CD8+T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma

The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined forin vitroinduction of peptide-specific CD8+T lymphocyte (CD8+TL) activity in peripheral blood mononuclear cells from...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2012-09, Vol.322 (1), p.86
Main Authors: Toyoshima, Takeshi, Kumamaru, Wataru, Hayashida, Jun-nosuke, Moriyama, Masahumi, Kitamura, Ryoji, Tanaka, Hideaki, Yamada, Akira, Itoh, Kyogo, Nakamura, Seiji
Format: Article
Language:English
Subjects:
Biopsy
Cancer
Cancer therapies
Cytotoxicity
Immunotherapy
Lymphocytes
Medical prognosis
Melanoma
Peptides
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined forin vitroinduction of peptide-specific CD8+T lymphocyte (CD8+TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8+TL andin vivoimmune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8+TL for at least one peptide were detectable in 21/35 patients (60.0%). The potent peptides were SART-1690in 9/35 (25.7%), SART-293, and ART475in 7/35 (20.0%), respectively. In the 9 patients with SART-1690-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1690-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3+T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1690, SART-293, and ART475could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2012.02.016